To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Clinical trial NCT05075408 · COMPLETED
Trial details
- NCT number
- NCT05075408
- Sponsor
- Galderma R&D
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-18
- Primary completion
- 2024-01-04
- Enrollment
- 258
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.